Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Suresh T. Chari

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-3924-0971; OpenAlex author ID A5048460582, A5135141153; NIH RePORTER profile ID 7136169. Sources: funder_awards.

Their work

Papers
90 (first author 11, last author 20)
Trials
2 (principal investigator on 1)
Grants
5
Labs led
2
Collaborators
270
Papers, trials and grants by year

2011: 1 paper · 2012: 5 papers · 2013: 4 papers · 2014: 4 papers · 2015: 7 papers · 2016: 5 papers · 2017: 6 papers · 2018: 10 papers, 1 grant · 2019: 6 papers · 2020: 10 papers · 2021: 10 papers, 2 trials · 2022: 4 papers, 1 grant · 2023: 5 papers · 2024: 3 papers, 1 grant · 2025: 2 papers · 2026: 8 papers, 2 grants

Papers 50 of 90

  1. Towards early detection of pancreatic cancer: The current status of cohort studies by the Diabetes-Pancreatic Ductal AdenoCarcinoma Working Group. First author DOI 10.1016/j.pan.2026.04.020↗
  2. Pancreatic cancer cell and stellate cell-derived exosome crosstalk mediates pancreatic cancer-related diabetes. Co-author DOI 10.1016/j.pan.2026.10.015↗
  3. Anatomically constrained deep learning for clinical-grade volumetric pancreatic cancer segmentation: development, validation, and architectural benchmarking. Co-author DOI 10.1038/s41698-026-01587-8↗
  4. Risk of Pancreatic Cancer in Glycemically Defined New-Onset Diabetes: A Prospective Cohort Study. Co-author DOI 10.1053/j.gastro.2025.06.025↗
  5. Heuriskance: a novel paradigm for systematic earlier detection of sporadic pancreatic cancer. Co-author DOI 10.1093/jnci/djaf291↗
  6. Next-generation AI for visually occult pancreatic cancer detection in a low-prevalence setting with longitudinal stability and multi-institutional generalisabi… Co-author DOI 10.1136/gutjnl-2025-337266↗
  7. Pancreatic Cancer Screening and Early Detection: Where Are We Now? Co-author DOI 10.1148/rg.250146↗
  8. Assessment of impending pancreatic cancer in a cohort of new onset diabetes on basis of biomarker trajectory Co-author DOI 10.64898/2026.08.06.26359908↗
  9. ENDPAC model for defining a high-risk group for pancreatic cancer: Strengths, limitations and the way forward. First author DOI 10.1016/j.pan.2025.11.007↗
  10. Diabetes and pancreatic cancer: a complex and confounding interplay. Co-author DOI 10.1136/gutjnl-2025-336806↗
  11. Proteomic profiling of small extracellular vesicles derived from mouse pancreatic cancer and stellate cells: Role in pancreatic cancer. Co-author DOI 10.1002/pmic.202300067↗
  12. Pancreatic Cancer-Induced Metabolic Dysregulation Syndrome: Clinical Profile, Proposed Mechanisms, and Unanswered Questions. Last author DOI 10.1053/j.gastro.2024.08.029↗
  13. Tumor Immune Microenvironment Promotes Cachexia in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002386↗
  14. Long-Term Outcomes and Risk of Pancreatic Cancer in Intraductal Papillary Mucinous Neoplasms. Co-author DOI 10.1001/jamanetworkopen.2023.37799↗
  15. Blood-based Migration Signature Biomarker Panel Discriminates Early Stage New Onset Diabetes related Pancreatic Ductal Adenocarcinoma from Type 2 Diabetes. Co-author DOI 10.1016/j.cca.2023.117567↗
  16. Bounding box-based 3D AI model for user-guided volumetric segmentation of pancreatic ductal adenocarcinoma on standard-of-care CTs. Co-author DOI 10.1016/j.pan.2023.05.008↗
  17. Management of Patients With Pancreatic Cancer Using the "Right Track" Model. Co-author DOI 10.1093/oncolo/oyad080↗
  18. Risk Prediction of Pancreatic Cancer in Patients With Recent-onset Hyperglycemia: A Machine-learning Approach. Co-author DOI 10.1097/mcg.0000000000001710↗
  19. Early Detection Initiative: A randomized controlled trial of algorithm-based screening in patients with new onset hyperglycemia and diabetes for early detectio… Co-author DOI 10.1016/j.cct.2021.106659↗
  20. Pancreatic Cancer is More Frequently Early Stage at Diagnosis in Surgically Resected Intraductal Papillary Mucinous Neoplasms With Preoperative Surveillance. Co-author DOI 10.1016/j.gastha.2022.07.004↗
  21. Prescription patterns of pancreatic enzyme replacement therapy for patients with pancreatic cancer in the United States. Co-author DOI 10.1016/j.hpb.2022.05.003↗
  22. Radiomics-based Machine-learning Models Can Detect Pancreatic Cancer on Prediagnostic Computed Tomography Scans at a Substantial Lead Time Before Clinical Diag… Co-author DOI 10.1053/j.gastro.2022.06.066↗
  23. Validation of the Enriching New-Onset Diabetes for Pancreatic Cancer Model in a Diverse and Integrated Healthcare Setting. Co-author DOI 10.1007/s10620-020-06139-z↗
  24. Pancreatic cancer in patients with autoimmune pancreatitis: A scoping review. Co-author DOI 10.1016/j.pan.2021.03.007↗
  25. Determining age and sex-specific distribution of pancreatic whole-gland CT attenuation using artificial intelligence aided image segmentation: Associations wit… Co-author DOI 10.1016/j.pan.2021.08.004↗
  26. Metabolic Surveillance for Those at High Risk for Developing Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2021.07.006↗
  27. Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review. First author DOI 10.1097/mpa.0000000000001762↗
  28. Early Detection of Pancreatic Cancer: Applying Artificial Intelligence to Electronic Health Records. Co-author DOI 10.1097/mpa.0000000000001882↗
  29. High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9. Co-author DOI 10.1158/1078-0432.ccr-20-0235↗
  30. Understanding the Contribution of Insulin Resistance to the Risk of Pancreatic Cancer. First author DOI 10.14309/ajg.0000000000001104↗
  31. Role of Pancreatic Stellate Cell-Derived Exosomes in Pancreatic Cancer-Related Diabetes: A Novel Hypothesis. Co-author DOI 10.3390/cancers13205224↗
  32. Potential Cost-Effectiveness of Risk-Based Pancreatic Cancer Screening in Patients With New-Onset Diabetes. Co-author DOI 10.6004/jnccn.2020.7798↗
  33. Methylated DNA in Pancreatic Juice Distinguishes Patients With Pancreatic Cancer From Controls. Co-author DOI 10.1016/j.cgh.2019.07.017↗
  34. New-Onset Diabetes, Longitudinal Trends in Metabolic Markers, and Risk of Pancreatic Cancer in a Heterogeneous Population. Co-author DOI 10.1016/j.cgh.2019.11.043↗
  35. Clinical impact of celiac ganglia metastasis upon pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2019.11.003↗
  36. Corrigendum to "Peripheral blood monocyte counts are elevated in the pre-diagnostic phase of pancreatic cancer: A population based study" [Pancreatology. 19 (8… Co-author DOI 10.1016/j.pan.2020.03.006↗
  37. Pancreatic ductal adenocarcinoma is associated with a unique endocrinopathy distinct from type 2 diabetes mellitus. Co-author DOI 10.1016/j.pan.2020.05.010↗
  38. International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international … Co-author DOI 10.1016/j.pan.2020.05.011↗
  39. Computerized tomography scan in pre-diagnostic pancreatic ductal adenocarcinoma: Stages of progression and potential benefits of early intervention: A retrospe… Last author DOI 10.1016/j.pan.2020.07.410↗
  40. Early detection of pancreatic cancer. First author DOI 10.1097/mog.0000000000000663↗
  41. Systemic Proteome Alterations Linked to Early Stage Pancreatic Cancer in Diabetic Patients. Co-author DOI 10.3390/cancers12061534↗
  42. Early Detection of Sporadic Pancreatic Ductal Adenocarcinoma: Problems, Promise, and Prospects Co-author DOI 10.7326/m19-2336↗
  43. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis. Co-author DOI 10.1002/jso.25681↗
  44. Peripheral blood monocyte counts are elevated in the pre-diagnostic phase of pancreatic cancer: A population based study. Co-author DOI 10.1016/j.pan.2019.10.002↗
  45. High-Grade Dysplasia in Resected Main-Duct Intraductal Papillary Mucinous Neoplasm (MD-IPMN) is Associated with an Increased Risk of Subsequent Pancreatic Canc… Last author DOI 10.1038/s41395-018-0403-2↗
  46. Phases of Metabolic and Soft Tissue Changes in Months Preceding a Diagnosis of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1053/j.gastro.2019.01.039↗
  47. Early Detection of Pancreatic Cancer: Opportunities and Challenges. Co-author DOI 10.1053/j.gastro.2019.01.259↗
  48. Pancreatic Cancer Following Incident Diabetes in African Americans and Latinos: The Multiethnic Cohort. Co-author DOI 10.1093/jnci/djy090↗
  49. Decreased Skeletal Muscle Volume Is a Predictive Factor for Poorer Survival in Patients Undergoing Surgical Resection for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s11605-018-3695-z↗
  50. Pancreatic Cancer and Diabetes Mellitus. First author DOI 10.1007/s11938-018-0197-8↗

Trials 2

  1. Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETEC… Principal investigator NCT03460769↗
  2. Early Detection Initiative for Pancreatic Cancer Study chair NCT04662879↗

Grants 5

  1. Developing methods for advancing the early detection of pancreatic ductal adenocarcinoma leveraging electronic medical records data R01CA289668↗
  2. The Exocrine and Endocrine Pancreas in Type 2 Diabetes, Pancreatitis and Cancer U01DK108288↗
  3. The Texas-Louisiana Alliance to Study Chronic Pancreatitis, Diabetes and Pancreatic Cancer U01DK126365↗
  4. Retrospective Cohort (REGARD) and Case-Control (PANDORA) Studies for Individuals with New-onset Diabetes (NOD) and New-onset Prediabetes (NOPD) in a Large Inte… AWARD pancan:2022-suresh-chari-md-retrospective-cohort-regard-and-case-con
  5. Administrative Core P50CA102701↗

Closest collaborators

The 25 strongest of 270 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anirban Maitra · 14 shared papers, 1 shared trial, 1 shared grant, 2015–2026 · strength 3.56
  2. Gloria M. Petersen · 19 shared papers, 2 shared grants, 2012–2026 · strength 2.28
  3. Santhi Swaroop Vege · 10 shared papers, 1 shared grant, 2015–2026 · strength 2.03
  4. Ying‐Qi Zhao · 3 shared papers, 1 shared grant, 2022–2026 · strength 1.92
  5. Ziding Feng · 8 shared papers, 1 shared trial, 2018–2026 · strength 1.51
  6. Shounak Majumder · 12 shared papers, 2019–2023 · strength 1.41
  7. Bechien U. Wu · 7 shared papers, 2020–2026 · strength 1.38
  8. Phil A. Hart · 12 shared papers, 2011–2026 · strength 1.35
  9. Mark D. Topazian · 7 shared papers, 1 shared grant, 2015–2026 · strength 1.33
  10. Ajit Harishkumar Goenka · 6 shared papers, 2020–2026 · strength 1.20
  11. Barbara J. Kenner · 9 shared papers, 2015–2026 · strength 1.13
  12. Lynn McCormick Matrisian · 6 shared papers, 2021–2026 · strength 1.08
  13. Michael J. Levy · 13 shared papers, 2015–2022 · strength 1.01
  14. William E Fisher · 3 shared papers, 1 shared trial, 2021–2026 · strength 1.00
  15. Jo Ann Rinaudo · 7 shared papers, 2016–2026 · strength 0.98
  16. Thomas C. Smyrk · 11 shared papers, 1 shared grant, 2012–2020 · strength 0.94
  17. Naoki Takahashi · 10 shared papers, 2017–2023 · strength 0.89
  18. Sovanlal Mukherjee · 4 shared papers, 2022–2026 · strength 0.82
  19. Mark Joseph Truty · 7 shared papers, 2015–2026 · strength 0.81
  20. Stephen Jacob Pandol · 8 shared papers, 2016–2026 · strength 0.78
  21. Avinash R. Kambadakone · 3 shared papers, 2022–2026 · strength 0.73
  22. Ayush Sharma · 7 shared papers, 2018–2020 · strength 0.72
  23. Jaime de la Fuente · 5 shared papers, 2019–2023 · strength 0.68
  24. Ferga C. Gleeson · 8 shared papers, 2015–2022 · strength 0.63
  25. Sudhir Srivastava · 8 shared papers, 2015–2022 · strength 0.62

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.